Aims: The single-nucleotide polymorphism, rs1805874, in the Calbindin1 gene has been associated with Parkinson's disease among the Japanese people, but not among Europeans or Americans. To help clarify these contrasting results, we conducted a case-control study to explore whether such an association exists among the Han Chinese. Methods: We used the ligase detection reaction to genotype the rs1805874 SNP in 514 Han Chinese with Parkinson's disease as well as in 475 healthy Han Chinese controls. Results: We identified a significant association between the A allele of rs1805874 and the risk of Parkinson's disease (OR 1.257, 95% CI 1.036-1.524, p = 0.020). Subgroup analysis revealed a significant association of the A allele with male gender (OR 1.306, 95% CI 1.009-1.691, p = 0.042) and late onset of disease (OR 1.247, 95% CI 1.010-1.540, p = 0.040). Conclusion: Our findings suggest that the A allele of rs1805874 is associated with risk of Parkinson's disease among the Han Chinese. Our results, combined with previous studies, suggest that rs1805874 is associated with Parkinson's disease in East Asians, but not Caucasians.
Get full access to this article
View all access options for this article.
References
1.
AbdullahR, BasakI, PatilKS, et al. (2015) Parkinson's disease and age: the obvious but largely unexplored link. Exp Gerontol, 68:33-38.
2.
BaldereschiM, Di CarloA, RoccaWA, et al. (2000) Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology, 55:1358-1363.
3.
BeckerC, JickSS, MeierCR (2008) Use of Statins and the Risk of Parkinson's Disease: a Retrospective Case-Control Study in the UK. Drug Saf, 31:399-407.
4.
BlandiniF (2010) An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol, 25:65-71.
5.
BlesaJ, Trigo-DamasI, Quiroga-VarelaA, et al. (2015) Oxidative stress and Parkinson's disease. Front Neuroanat, 9:91.
6.
HughesAJ, DanielSE, KilfordL, et al. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55:181-184.
7.
ChanCS, GuzmanJ N, IlijicE, et al. (2007) ‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease. Nature, 447:1081-1086.
ChardPS, BleakmanD, ChristakosS, et al. (1993) Calcium buffering properties of calbindin D28k and parvalbumin in rat sensory neurones. J Physiol, 472:341-357.
DamierP, HirschEC, AgidY, et al. (1999) The substantia nigra of the human brain II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 122:1437-1448.
12.
DauerW, PrzedborskiS (2003) Parkinson's disease: mechanisms and models. Neuron, 39:889-909.
13.
DicksonDW (2012) Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med, 2:pii: a009258.
14.
DorseyER, ConstantinescuR, ThompsonJP, et al. (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68:384-386.
15.
FindleyLJ (2007) The economic impact of Parkinson's disease. Parkinsonism Relat Disord, 13:S8-S12.
16.
GermanDC, ManayeKF, SonsallaPK, et al. (1992) Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k- containing cells. Ann N Y Acad Sci, 648:42-62.
17.
GhaheriM, KahriziD, YariK, et al. (2016) A comparative evaluation of four DNA extraction protocols from whole blood sample. Cell Mol Biol (Noisy-le-grand), 62:120-124.
18.
HaaxmaCA, BloemBR, BormGF, et al. (2007) Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry, 78:819-824.
19.
IacopinoAM, ChristakosS (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA, 87:4078-4082.
20.
JancaA (2002) Parkinson's disease from WHO perspective and a public health point of view. Parkinsonism Relat Disord, 9:3-6.
LiangCL, SintonCM, SonsallaPK, et al. (1996) Midbrain Dopaminergic Neurons in the Mouse that Contain Calbindin-D28k Exhibit Reduced Vulnerability to MPTP-induced Neurodegeneration. Neurodegeneration, 5:313-318.
23.
MaraganoreDM, de AndradeM, LesnickTG, et al. (2005) High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet, 77:685-693.
24.
MataIF, YearoutD, AlvarezV, et al. (2011) Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. Mov Disord, 26:819-823.
25.
MattsonMP, RychlikB, ChuC, et al. (1991) Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-D28k in cultured hippocampal neurons. Neuron, 6:41-51.
26.
MizutaI, TsunodaT, SatakeW, et al. (2008) Calbindin 1, fibroblast growth factor 20, and α-synuclein in sporadic Parkinson's disease. Hum Genet, 124:89-94.
27.
MosharovEV, LarsenKE, KanterE, et al. (2009) Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron, 62:218-229.
28.
NakasoK, TajimaN, HorikoshiY, et al. (2014) The estrogen receptor β-PI3K/Akt pathway pathway mediates the cytoprotective effects of tocotrienol in a cellular Parkinson's disease model. Biochim Biophys Acta, 1842:1303-1312.
29.
NoyceAJ, BestwickJP, Silveira-MoriyamaL, et al. (2012) Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol, 72:893-901.
30.
OrreniusS, ZhivotovskyB, NicoteraP (2003) Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol, 4:552-565.
31.
PersechiniA, MoncriefND, KretsingerRH (1989) The EF-hand family of calcium-modulated proteins. Trends Neurosci, 12:462-467.
32.
PringsheimT, JetteN, FrolkisA, et al. (2014) The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord, 29:1583-1590.
33.
RitzB, RhodesSL, QianL, et al. (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol, 67:600-606.
34.
SambrookJ, RussellDW, RussellDW (2001) Molecular Cloning: A Laboratory Manual (3-Volume Set). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
35.
Soto-OrtolazaAI, BehrouzB, WiderC, et al. (2010) Calbindin-1 association and Parkinson's disease. Eur J Neurol, 17:208-211.
36.
SunS, LiF, GaoX, et al. (2011) Calbindin-D28K inhibits apoptosis in dopaminergic neurons by activation of the PI3-kinase-Akt signaling pathway. Neuroscience, 199:359-367.
37.
TannerCM, OttmanR, GoldmanSM, et al. (1999) Parkinson disease in twins: an Etiologic study. JAMA, 281:341-346.
38.
ThomasG, SinvilleR, SuttonS, et al. (2004) Capillary and microelectrophoretic separations of ligase detection reaction products produced from low-abundant point mutations in genomic DNA. Electrophoresis, 25:1668-1677.
39.
Van Den EedenSK, TannerCM, BernsteinAL, et al. (2003). Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemio, 157:1015-1022.
40.
WardCD, DuvoisinRC, InceSE, et al. (1983) Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology, 33:815-824.
41.
WilsonCJ, CallawayJC (2000) Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol, 83:3084-3100.
42.
WootenGF, CurrieLJ, BovbjergVE, et al. (2004) Are men at greater risk for Parkinson's disease than women?. J Neurol Neurosurg Psychiatry, 75:637-639.
43.
WuX, TangKF, LiY, XiongYY, et al. (2012) Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord, 18:722-730.
44.
YamadaT, McGeerPL, BaimbridgeKG, et al. (1990) Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res, 526:303-307.
45.
YangX, ZhaoQ, AnR, et al. (2016) Mutational scanning of the CHCHD2 gene in Han Chinese patients with Parkinson's disease and meta-analysis of the literature. Parkinsonism Relat Disord, 29:42-46.
